When CureDuchenne invested in Avidity Biosciences in 2018, it was with strong belief in their technology and the promise of what it might be able to achieve in Duchenne. We congratulate Avidity on all their success to date, and celebrate with them on this important new development. And we look forward to working with Novartis in the future.
Read the full press release HERE
The post Avidity Biosciences to be acquired by Novartis appeared first on CureDuchenne.